Your browser doesn't support javascript.
A case of successful management of adult-onset linear IgA bullous disease with sulfasalazine during the COVID-19 pandemic
British Journal of Dermatology ; 186(6):e247, 2022.
Article in English | EMBASE | ID: covidwho-1956689
ABSTRACT
Linear IgA bullous disease (LABD) is a rare, acquired, autoimmune, pruritic and blistering skin condition. Dapsone is a first line treatment option, however there are limited options if this fails, or was contraindicated. We present a case of successful management of LABD with sulfasalazine. A 46-year-old white woman with LABD was commenced on high-dose corticosteroids. She failed weaning, and dapsone was contraindicated due to a history of primary sclerosing cholangitis and risk of hepatitis. Following the failure of mycophenolate mofetil, sulfasalazine was trialled, and successfully controlled both the patient's LABD and ulcerative colitis. There is little literature on the use of sulfasalazine in dermatological conditions. We present sulfasalazine as an option for patients who are unable to tolerate classically used treatments for LABD, or in those who have a dual diagnosis, as in this case, allowing for one agent to manage both conditions. Furthermore, the National Institute for Health and Care Excellence (NICE) guidance mentions sulfasalazine as one of the few drugs that can be continued during the COVID-19 pandemic, and its use spared this patient from the significant immunosuppression associated with other treatment modalities.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: British Journal of Dermatology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: British Journal of Dermatology Year: 2022 Document Type: Article